Browse Studies — Arctuva

Phase 1

Phase I/II Study to Evaluate the Feasibility and Efficacy of Sequential Abemaciclib and Gemcitabine Treatment in Patients With Retinoblastoma (Rb)+ Sarcomas

This phase I/II trial tests the side effects and best dose of abemaciclib when added to gemcitabine and compares the effectiveness of that treatment to the usu…

Advanced Dedifferentiated LiposarcomaAdvanced LeiomyosarcomaAdvanced Soft Tissue Sarcoma+5 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06498648

Phase 1

A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of ADCE-D01, a Humanized Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients With Metastatic and/or Unresectable Soft Tissue Sarcoma

The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01.

Metastatic Soft Tissue SarcomaUnresectable Soft Tissue Sarcoma

Estimated

~$10 – $7,500

Adcendo ApSNCT06797999

Phase 1

Phase I/ II Study of Pulmonary Suffusion to Control Minimal Residual Disease in Resectable or Ablatable Sarcoma or Colorectal Pulmonary Metastases

This phase I/II trial studies the side effects of pulmonary suffusion in controlling minimal residual disease in patients with sarcoma or colorectal carcinoma …

Metastatic Bone SarcomaMetastatic Malignant Neoplasm in the LungMetastatic Soft Tissue Sarcoma+3 more

Estimated

~$10 – $7,500

Roswell Park Cancer InstituteNCT03965234

Phase 1

SAINT: A Phase 1/2 Study of Safe Amounts of IPLIMUMAB, NIVOLUMAB and TRABECTEDIN for Previously Treated Advanced Soft Tissue Sarcoma (STS)

This is an open label, dose-seeking phase 1/2 study using escalating doses of TRABECTEDIN given intravenously with defined doses of IPILIMUMAB and NIVOLUMAB ba…

Advanced Soft Tissue SarcomaMetastatic Soft Tissue Sarcoma

Estimated

~$10 – $6,250

Sarcoma Oncology Research Center, LLCNCT03138161